A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the oral glucose load and [3H]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant improvements were observed in hepatic steatosis, hepatocellular ballooning, necrosis, and inflammation; however, fibrosis reduction did not reach statistical significance compared with placebo.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [202]
In the citing paper
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [146]
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [92]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Self-citationYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Research works printed but not linked: 3
- 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- 10.1172/JCI22422 · DOI · Paper page
Cited by
Items 501–600 of 1,003
Obesity as the common soil of non‐alcoholic fatty liver disease and diabetes: Role of adipokines
Hui, E., Xu, A., Yang, H. B., & Lam, K. S. L. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12093 · Cited by 88
Ohki, T., Isogawa, A., Toda, N., & Tagawa, K. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0383-1 · Cited by 83
“In particular, trials of glucose-lowering agents such as metformin and pioglitazone have provided promising results [20, 21].”
BackgroundZib, I., Jacob, A. N., Lingvay, I., Salinas, K., McGavock, J. M., Raskin, P., & Szczepaniak, L. S. (2007) · Journal of Investigative Medicine · doi:10.2310/6650.2007.00003 · Cited by 79
Reproducibility of 3.0 Tesla magnetic resonance spectroscopy for measuring hepatic fat content
van Werven, J. R., Hoogduin, J. M., Nederveen, A. J., van Vliet, A. A., Wajs, E., Vandenberk, P., Stroes, E. S. G., & Stoker, J. (2009) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21837 · Cited by 79
“Noninvasive (1)H-MRS is also suitable to determine HTGC and follow up patients in clinical trails (17).”
BackgroundSven M., F., Pierre, B., Manal F., A., Quentin M., A., Elisabetta, B., Vlad, R., Philippe, H.-M., Bruno, S., Jean-Louis, J., Pierre, B., et al. (2020) · Contemporary Clinical Trials · doi:10.1016/j.cct.2020.106170 · Cited by 78
Galiero, R., Caturano, A., Vetrano, E., Cesaro, A., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., Moscarella, E., Gragnano, F., et al. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2203082 · Cited by 99
Balmer, M. L., Siegrist, K., Zimmermann, A., & Dufour, J. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02037.x · Cited by 78
Han, S., Jiao, J., Zhang, W., Xu, J., Wan, Z., Zhang, W., Gao, X., & Qin, L. (2015) · Scientific Reports · doi:10.1038/srep15256 · Cited by 87
Ballestri, S., Nascimbeni, F., Romagnoli, D., Baldelli, E., & Lonardo, A. (2016) · Advances in Therapy · doi:10.1007/s12325-016-0306-9 · Cited by 80
“study, pioglitazone significantly improved aminotransferase levels, steatosis, ballooning, and inflammation in NASH patients with impaired glucose tolerance or T2D [202].”
BackgroundInfluentialHetherington, A. M., Sawyez, C. G., Zilberman, E., Stoianov, A. M., Robson, D. L., & Borradaile, N. M. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447866 · Cited by 80
Amiri, H. L., Agah, S., Azar, J. T., Hosseini, S., Shidfar, F., & Mousavi, S. N. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.09.020 · Cited by 85
Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Abdul‐Ghani, M. A., Jayyousi, A., DeFronzo, R. A., Asaad, N., & Suwaidi, J. M. S. A. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171010115119 · Cited by 82
Self-citationOxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma
Uchida, D., Takaki, A., Oyama, A., Adachi, T., Wada, N., Onishi, H., & Okada, H. (2020) · Nutrients · doi:10.3390/nu12061576 · Cited by 91
“One six-month randomized study of pioglitazone plus hypocaloric diet showed a plasma aminotransferase decrease, insulin sensitivity improvement, hepatic fat content decrease, and a histopathological reduction in liver necro-inflammation [132].”
BackgroundModern approach to the clinical management of non-alcoholic fatty liver disease
Ben, M. D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i26.8341 · Cited by 77
Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus
Mori, K., Emoto, M., Araki, T., Yokoyama, H., Lee, E., Teramura, M., Koyama, H., Shoji, T., Inaba, M., & Nishizawà, Y. (2008) · Metabolism · doi:10.1016/j.metabol.2008.04.019 · Cited by 80
“Interestingly, several reports have shown that thiazolidinediones including pioglitazone improve the hepatocellular lipid content, whereas metformin did not affect it [13,14].”
BackgroundThe role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
Van Wagner, L. B., & Rinella, M. E. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11403809 · Cited by 77
“Belfort and colleagues published the first double-blind, placebo-controlled trial using diet plus 45 mg of pioglitazone per day compared with diet plus placebo for 6 months in 55 patients with glucose intolerance or diabetes and NASH [Belfort et al. 2006].”
MethodClemenz, M., Frost, N., Schupp, M., Caron, S., Foryst‐Ludwig, A., Böhm, C., Hartge, M., Gust, R., Staels, B., Unger, T., et al. (2008) · Diabetes · doi:10.2337/db07-0839 · Cited by 86
Vatner, D. F., Goedeke, L., Camporez, J.-P. G., Lyu, K., Nasiri, A. R., Zhang, D., Bhanot, S., Murray, S. F., Still, C. D., Gerhard, G. S., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4579-1 · Cited by 76
Zhang, L.-Y., Qu, X.-N., Sun, Z.-Y., & Zhang, Y. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.01.007 · Cited by 76
Filozof, C., Goldstein, B. J., Williams, R. N., & Sanyal, A. (2015) · Drugs · doi:10.1007/s40265-015-0437-3 · Cited by 77
“001) and there was a trend toward improvement in fibrosis [76].”
BackgroundRatziu, V., Caldwell, S., & Neuschwander-Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.24042 · Cited by 76
“Adiponectin increase reflects a strong improvement in hepatic IS, by as much as 48%.(22) Only one study showed no reduction in HOMA, only less deterioration in serum glucose or HbA1c levels.”
BackgroundInfluentialJornayvaz, F. R., Lee, H.-Y., Jurczak, M. J., Alves, T. C., Guebre-Egziabher, F., Guigni, B. A., Zhang, D., Samuel, V. T., Silva, J. E., & Shulman, G. I. (2012) · Endocrinology · doi:10.1210/en.2011-1793 · Cited by 76
Insulin sensitizers for the treatment of non-alcoholic fatty liver disease
Öztürk, Z. A., & Kadayıfçı, A. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i4.199 · Cited by 85
Hepatocyte-specific, PPARγ-regulated mechanisms to promote steatosis in adult mice
Greenstein, A. W., Majumdar, N., Yang, P., Subbaiah, P. V., Kineman, R. D., & Córdoba‐Chacón, J. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0447 · Cited by 89
Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities
Manka, P., Zeller, A., & Syn, W.-K. (2019) · Drugs · doi:10.1007/s40265-019-01126-9 · Cited by 76
Antifibrotic Therapies in the Liver
Schuppan, D., & Mehal, W. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550055 · Cited by 75
Xing, B., Zhao, Y., Dong, B., Zhou, Y., Lv, W., & Zhao, W. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13237 · Cited by 73
Sonographic hepatorenal ratio: A noninvasive method to diagnose nonalcoholic steatosis
Borges, V. F. D. A. E., Diniz, A. L. D., Cotrim, H. P., Rocha, H. L. O. G., & de Andrade, N. B. (2012) · Journal of Clinical Ultrasound · doi:10.1002/jcu.21994 · Cited by 79
Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease
Yoon, H., & Soo, B. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v6.i11.800 · Cited by 83
Examining the safety of PPAR agonists – current trends and future prospects
Bortolini, M., Wright, M. B., Bopst, M., & Balas, B. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.741585 · Cited by 75
“Glitazones are therefore attractive candidates for treatment of NASH because of their insulin-sensitizing, anti-inflammatory and antifibrotic properties, as well as their effects on liver enzyme levels, which have been demonstrated in several studies [60-62].”
BackgroundSelf-citationKim, W., Kim, B. G., Lee, J. S., Lee, C. K., Yeon, J. E., Chang, M. S., Kim, J. H., Kim, H., Yi, S., Lee, J., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13981 · Cited by 75
“zone-treated group, while there was no difference (0%) in the placebo-treated group.(15) In another study, there was a 4.”
Lee, Y.-M., Sutedja, D. S., Wai, C. T., Dan, Y.-Y., Aung, M., Zhou, L., Cheng, C. L., Wee, A., & Lim, S. G. (2008) · Hepatology International · doi:10.1007/s12072-008-9058-1 · Cited by 78
“A recent placebo-controlled trial of Pioglitazone in subjects with NASH and impaired glucose tolerance or type 2 diabetes showed metabolic and histological improvement in those treated with Pioglitazone [18].”
BackgroundNon-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments
Scorletti, E., Calder, P. C., & Byrne, C. D. (2011) · Endocrine · doi:10.1007/s12020-011-9530-x · Cited by 80
“Pioglitazone has been shown to improve steatosis, ballooning necrosis and inflammation, but may have little effect on fibrosis in patients with NAFLD [86].”
BackgroundPharmacological interventions for non-alcohol related fatty liver disease (NAFLD)
Lombardi, R., Onali, S., Thorburn, D., Davidson, B. R., Gurusamy, K. S., & Tsochatzis, E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011640.pub2 · Cited by 74
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review
Blazina, I., & Selph, S. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1200-8 · Cited by 74
Han, E., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010259 · Cited by 88
“Moreover, the response rate to TZD treatment is relatively low (approximately 50%) in NAFLD [8,10,11].”
BackgroundLu, H., Zeng, L., Liang, B., Shu, X., & Xie, D. (2009) · Archives of Medical Research · doi:10.1016/j.arcmed.2009.07.009 · Cited by 87
Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging
Mashhood, A., Railkar, R., Yokoo, T., Levin, Y., Clark, L., Fox‐Bosetti, S., Middleton, M. S., Riek, J., Kauh, E., Dardzinski, B. J., et al. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.23928 · Cited by 74
Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan, D., Clar, C., Ghouri, N., Henderson, R., Gurung, T., Preiss, D., Sattar, N., Fraser, A., & Waugh, N. (2011) · Health Technology Assessment · doi:10.3310/hta15380 · Cited by 74
A critical review of endpoints for non-cirrhotic NASH therapeutic trials
Ratziu, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.001 · Cited by 74
“range of 30–40%, which is maintained throughout the entire treatment period.(11,15,38,41) ALT values usually do not change in the placebo arm,(14,15,41)”
BackgroundPeroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease
Choudhary, N. S., Kumar, N., & Duseja, A. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.06.004 · Cited by 73
Tsochatzis, E. A., Papatheodoridis, G., Manesis, E. K., Kafiri, G., & Archimandritis, A. J. (2007) · Journal of Hepatology · doi:10.1016/s0168-8278(07)62365-4 · Cited by 73
How should we manage patients with non‐alcoholic fatty liver disease in 2007?
Chan, H. L., de Silva, H. J., Leung, N. W. Y., Lim, S. G., Farrell, G. C., & NAFLD, T. A. W. P. O. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04977.x · Cited by 77
Kajikawa, S., Harada, T., Kawashima, A., Imada, K., & Mizuguchi, K. (2009) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2009.02.004 · Cited by 77
“In a clinical trial, the treatment of NASH patients with pioglitazone improved this metabolic and histological disorder, and reduced the content of liver fat [47].”
Treating the metabolic syndrome
Bianchi, C., Penno, G., Romero, F., Prato, S. D., & Miccoli, R. (2007) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.3.491 · Cited by 83
Dong, Y., Lv, Q., Li, S., Wu, Y., Li, L., Li, J., Zhang, F., Sun, X., & Tong, N. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2016.11.009 · Cited by 71
Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis
Loria, P., Lonardo, A., & Targher, G. (2008) · Clinical Science · doi:10.1042/cs20070311 · Cited by 72
Type 2 diabetes in younger adults: the emerging UK epidemic
Wilmot, E. G., Davies, M. J., Yates, T., Benhalima, K., Lawrence, I. G., & Khunti, K. (2010) · Postgraduate Medical Journal · doi:10.1136/pgmj.2010.100917 · Cited by 72
“A ‘multi-hit’ hypothesis has been proposed to describe the pathogenesis of NAFLD.63 64 Insulin resistance and the associated increase in free fatty acids that are absorbed by the liver represent the first ‘hit’ and the development of steatosis.”
BackgroundInfluentialInsulin Resistance Among Patients With Chronic Hepatitis C: Etiology and Impact on Treatment
Harrison, S. A. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.024 · Cited by 77
Self-citationThe current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 75
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 77
“Of note, the improvement in stea-tohepatitis with pioglitazone has been reported with doses of 30 – 45 mg/day (29 – 34).”
BackgroundSelf-citationMitochondria and Redox Signaling in Steatohepatitis
Morris, E. M., Rector, R. S., Thyfault, J. P., & Ibdah, J. A. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3795 · Cited by 72
“Several human trials have observed improvement in steatosis and liver histology in steatohepatitis after TZD therapy alone or in conjunction with other treatment modalities (2, 14, 142, 171, 186).”
Nonalcoholic fatty liver disease as a component of the metabolic syndrome
Khashab, M. A., Liangpunsakul, S., & Chalasani, N. (2008) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0012-0 · Cited by 74
Role of hepatic iron in non‐alcoholic steatohepatitis
Sumida, Y., Yoshikawa, T., & Okanoue, T. (2009) · Hepatology Research · doi:10.1111/j.1872-034x.2008.00442.x · Cited by 73
Sofer, E., Boaz, M., Matas, Z., Mashavi, M., & Shargorodsky, M. (2011) · Metabolism · doi:10.1016/j.metabol.2011.01.011 · Cited by 73
“[10] Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al.”
BackgroundHuard, K., Brown, J. A., Jones, J. E. C., Cabral, S., Futatsugi, K., Gorgoglione, M. F., Lanba, A., Vera, N. B., Zhu, Y., Yan, Q., et al. (2015) · Scientific Reports · doi:10.1038/srep17391 · Cited by 72
Tsochatzis, E. A., Papatheodoridis, G., Manesis, E. K., Kafiri, G., TINIAKOS, D. G., & Archimandritis, A. J. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03538.x · Cited by 87
McVicker, B. L., & Bennett, R. G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00318 · Cited by 85
“…with pioglitazone or placebo in conjunction with a hypocaloric diet showed improvements in liver function, steatosis and inflammation, but no difference in fibrosis compared Frontiers in Pharmacology | www.frontiersin.org 8 May 2017 | Volume 8 | Article 318 with placebo (Belfort et al., 2006).”
BackgroundDongiovanni, P., Paolini, E., Corsini, A., Sirtori, C. R., & Ruscica, M. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13519 · Cited by 77
Cooreman, M. P., Butler, J., Giugliano, R. P., Zannad, F. M., Dzen, L., Huot-Marchand, P., Baudin, M., Beard, D. R., Junien, J., Broqua, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47919-9 · Cited by 83
Ratziu, V., Bugianesi, E., Dixon, J. B., Fassio, E., Ekstedt, M., Charlotte, F., Kechagias, S., Poynard, T., & Olsson, R. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03425.x · Cited by 73
Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease
Blazer‐Yost, B. L., Haydon, J., Eggleston‐Gulyas, T., Chen, J.-H., Wang, X., Gattone, V. H., & Torres, V. E. (2010) · PPAR Research · doi:10.1155/2010/274376 · Cited by 75
Kurosaki, M., Hosokawa, T., Matsunaga, K., Hirayama, I., Tanaka, T., Sato, M., Yasui, Y., Tamaki, N., Ueda, K., Tsuchiya, K., et al. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00692.x · Cited by 73
Psoriasis and non‐alcoholic fatty liver disease
Wenk, K. S., Arrington, K., & Ehrlich, A. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2010.03841.x · Cited by 80
Inflammation is independent of steatosis in a murine model of steatohepatitis
Wang, W., Xu, M., Cai, Y., Zhou, Z., Cao, H., Mukhopadhyay, P., Pacher, P., Zheng, S., Gonzalez, F. J., & Gao, B. (2017) · Hepatology · doi:10.1002/hep.29129 · Cited by 70
Current Perspectives Regarding Stem Cell-Based Therapy for Liver Cirrhosis
Kwak, K.-A., Cho, H.-J., Yang, J.-Y., & Park, Y.-S. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/4197857 · Cited by 69
Gerges, S. H., Wahdan, S. A., Elsherbiny, D. A., & El‐Demerdash, E. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119220 · Cited by 84
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Ng, C. H., Xiao, J., Lim, W. H., Chin, Y. H., Yong, J. N., Tan, D. J. H., Tay, P., Syn, N., Foo, R., Chan, M., et al. (2022) · Hepatology · doi:10.1002/hep.32315 · Cited by 69
Ursodeoxycholic acid with vitamin E in patients with nonalcoholic steatohepatitis: Long-term results
Pietu, F. J., Guillaud, O., Walter, T., Vallin, M., Hervieu, V., Scoazec, J., & Dumortier, J. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2011.10.011 · Cited by 72
Histological Assessment of NAFLD
Bédossa, P. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4062-0 · Cited by 80
Berberine ameliorates fatty acid-induced oxidative stress in human hepatoma cells
Sun, Y., Yuan, X., Zhang, F., Han, Y., Chang, X., Xu, X., Li, Y., & Gao, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-11860-3 · Cited by 71
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 67
“A modest effect on fibrosis has been reported in some of these trials (28,30).”
BackgroundSelf-citationBeneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kim, K., & Lee, B. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0137 · Cited by 73
“0137 mation of liver biopsy-confirmed NASH patients.(31) Meta-analyses agreed with the beneficial effects of pioglitazone on lobular inflammation.”
BackgroundKořínková, L., Pražienková, V., Černá, L., Karnošová, A., Železná, B., Kuneš, J., & Maletínská, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.597583 · Cited by 81
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s004 · Cited by 139
Nonalcoholic Fatty Liver Disease
Paredes, A. H., Torres, D. M., & Harrison, S. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.005 · Cited by 76
Self-citationTranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis†
Uno, M., Kurita, S., Misu, H., Ando, H., Ota, T., Nagata, N., Kita, Y., Nabemoto, S., Akahori, H., Zen, Y., et al. (2008) · Hepatology · doi:10.1002/hep.22338 · Cited by 70
Metabolic alterations and chronic hepatitis C: treatment strategies
Adinolfi, L. E., Restivo, L., Zampino, R., Lonardo, A., & Loria, P. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.597742 · Cited by 72
“Similarly, treatment strategies aimed at improving insulin resistance with pioglitazone, a PPAR agonist or metformin before or in combination with SOC may lead to increased response rate in chronic hepatitis C patients [70-73].”
BackgroundA Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
Hossain, N., Kanwar, P., & Mohanty, S. R. (2016) · Gastroenterology Research and Practice · doi:10.1155/2016/7109270 · Cited by 76
“Weight loss through bariatric surgery has been proposed as a possible treatment option for nonalcoholic fatty liver disease because of its positive effect on liver histology.”
BackgroundAntidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., Ono, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061907 · Cited by 68
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reduci…”
BackgroundSelf-citationMahjoubin‐Tehran, M., Vincentis, A. D., Mikhailidis, D. P., Atkin, S. L., Mantzoros, C. S., Jamialahmadi, T., & Sahebkar, A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101049 · Cited by 76
“Mild oedema and fatigue developed in 1 subject who received pioglitazone, but no other adv erse effect were observed [46].”
BackgroundLin, R., Sun, Q., Xin, X., Ng, C. H., Valenti, L. V. C., Hu, Y., Zheng, M., & Feng, Q. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156043 · Cited by 73
Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Beaton, M. D. (2012) · Canadian Journal of Gastroenterology · doi:10.1155/2012/725468 · Cited by 75
An overview of nonalcoholic steatohepatitis: past, present and future directions.
Pascale, A., Pais, R., & Ratziu, V. (2010) · PubMed · Cited by 71
Greuter, T., Malhi, H., Gores, G. J., & Shah, V. H. (2017) · JCI Insight · doi:10.1172/jci.insight.95354 · Cited by 67
Kalavalapalli, S., Bril, F., Koelmel, J. P., Abdo, K., Guingab, J., Andrews, P., Li, W.-Y., Jose, D., Yost, R. A., Frye, R. F., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00023.2018 · Cited by 66
Self-citationControversies in the Diagnosis and Management of NAFLD and NASH.
Rinella, M. E., Loomba, R. S., Caldwell, S. H., Kowdley, K. V., Charlton, M., Tetri, B. A., & Harrison, S. A. (2014) · PubMed Central · Cited by 76
Self-citationTriglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent
Semova, I., & Biddinger, S. B. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.12.001 · Cited by 76
Xiao, F., Waldrop, S. L., Khimji, A.-K., & Kilic, G. (2012) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00175.2012 · Cited by 73
Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review
Arab, J. P., Candia, R., Zapata, R., Muñoz, C., Arancibia, J. P., Poniachik, J., Soza, A., Fuster, F., Brahm, J., Sanhueza, E., et al. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.12182 · Cited by 71
Pleiotropic effects of thiazolidinediones
Rizos, C., Liberopoulos, E., Mikhailidis, D., & Elisaf, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.7.1087 · Cited by 65
“In another study, patients (n = 55) with either IGT or T2DM and biopsy-confirmed NASH were randomized to a hypocaloric diet plus either pioglitazone or placebo [167] .”
BackgroundKang, S., Moon, M. K., Kim, W., & Koo, B. K. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12598 · Cited by 64
(2021) · doi:10.1007/s12072-021-10242-2 · Cited by 64
Diabetic Cardiomyopathy: A Brief Summary on Lipid Toxicity
Ke, J., Pan, J., Lin, H., & Gu, J. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14224 · Cited by 70
“verse effects (mild oedema, body weight gain, fatigue, and fracture) constrained their wide application.(117,118) However, further evidence revealed that the glucose-lowering benefits of TZDs were independent of PPAR-γ, which is the cause of side effects.”
BackgroundMechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders
Lim, S. K., Oh, T. J., & Koh, K. K. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.107 · Cited by 72
Gout and risk of non-alcoholic fatty liver disease
Kuo, C.-F., Yu, K.-H., Luo, S.-F., Chiu, C.-T., Ko, Y.-S., Hwang, J.-S., Tseng, W.-Y., Chang, H.-C., Chen, H.-W., & See, L. (2010) · Scandinavian Journal of Rheumatology · doi:10.3109/03009741003742797 · Cited by 64
Joo, I., Lee, J. M., Yoon, J. H., Jang, J. J., Han, J. K., & Choi, B. I. (2013) · Radiology · doi:10.1148/radiol.13122506 · Cited by 67
Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease
Grattagliano, I., Montezinho, L. P., Oliveira, P. J., Frühbeck, G., Gómez‐Ambrosi, J., Montecucco, F., Carbone, F., Wieckowski, M. R., Wang, D. Q. ‐., & Portincasa, P. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.11.020 · Cited by 70
The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis
Schuppan, D., Gorrell, M. D., Klein, T., Mark, M., & Afdhal, N. H. (2009) · Liver International · doi:10.1111/j.1478-3231.2010.02264.x · Cited by 74
Metadata
- Authors
- Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., & Cusi, K.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Brooke Army Medical Center (US)
- South Texas Veterans Health Care System (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2297-2307
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103156933
- Cited by
- 1,827
- References
- 38
- Citations by year
- 2026: 44 · 2025: 73 · 2024: 83 · 2023: 78 · 2022: 84 · 2021: 93 · 2020: 73 · 2019: 74 · 2018: 70 · 2017: 93 · 2016: 98 · 2015: 106 · 2014: 92 · 2013: 87 · 2012: 85
- FWCI
- 91.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholic steatohepatitis, thiazolidinediones, insulin resistance, hypocaloric diet, hepatic steatosis, hepatic insulin sensitivity, necroinflammation, liver fibrosis, glucose tolerance, type 2 diabetes, impaired glucose tolerance, hepatic aminotransferases, drug safety, adverse effects
- MeSH terms
- Pioglitazone, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Double-Blind Method, Fatty Liver, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Liver Cirrhosis, Male, Middle Aged, Necrosis, Glucose Intolerance, Caloric Restriction, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.